intravenous glutathione pharmacokinetics half-life Terminal and the time required to reach steady-state Half-Life (t½) | NIH

Although KPV isnt yet an FDA-approved drug with widespread human use, these practical perspectives have allowed us to deduce its relative position in the larger peptide landscape

There was a positive trend in the Composite SLE Responder Index in the Intention-to-treat (ITT) cohort, and post-hoc analysis showed that the BILAG secondary endpoint was met for a number of subgroups dosing levels, including low or no steroids, seropositivity, and patients with 2 grade BILAG improvement

An additional consideration is the methodological quality of the included trials

mRNA therapies: pioneering a new era in rare genetic disease treatment